Search research articles
Contact Us
Filters
Showing results (111-120 of 162) with videos related to
Page
of 17
Sort By:
Blood
|
May 6, 2003
Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation
Simona Soverini, Michele Cavo, Claudia Cellini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2005
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia
Simona Soverini, Giovanni Martinelli, Gianantonio Rosti, et al.
Haematologica
|
June 11, 2010
The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party
Ilaria Iacobucci, Annalisa Lonetti, Francesca Paoloni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2006
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment
Ilaria Iacobucci, Gianantonio Rosti, Marilina Amabile, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 2008
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML
Francesca Palandri, Ilaria Iacobucci, Giovanni Martinelli, et al.
Frontiers in Oncology
|
October 18, 2021
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia
Samantha Bruno, Lorenza Bandini, Agnese Patuelli, et al.
Biomedicines
|
April 30, 2021
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a
Maria Chiara Fontana, Jacopo Nanni, Andrea Ghelli Luserna di Rorà, et al.
Blood
|
December 3, 2003
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
Gianantonio Rosti, Giovanni Martinelli, Simona Bassi, et al.
Haematologica
|
August 2, 2007
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study
Michele Baccarani, Daniela Cilloni, Michela Rondoni, et al.
Cancer
|
January 3, 2014
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement
Simona Soverini, Caterina De Benedittis, Cristina Papayannidis, et al.
Page
of 17
Search research articles
Search
Showing results (111-120 of 162) with videos related to
Sort By:
Page
of 17
Blood
|
May 6, 2003
Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation
Simona Soverini, Michele Cavo, Claudia Cellini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2005
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia
Simona Soverini, Giovanni Martinelli, Gianantonio Rosti, et al.
Haematologica
|
June 11, 2010
The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party
Ilaria Iacobucci, Annalisa Lonetti, Francesca Paoloni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2006
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment
Ilaria Iacobucci, Gianantonio Rosti, Marilina Amabile, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 2008
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML
Francesca Palandri, Ilaria Iacobucci, Giovanni Martinelli, et al.
Frontiers in Oncology
|
October 18, 2021
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia
Samantha Bruno, Lorenza Bandini, Agnese Patuelli, et al.
Biomedicines
|
April 30, 2021
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a
Maria Chiara Fontana, Jacopo Nanni, Andrea Ghelli Luserna di Rorà, et al.
Blood
|
December 3, 2003
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
Gianantonio Rosti, Giovanni Martinelli, Simona Bassi, et al.
Haematologica
|
August 2, 2007
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study
Michele Baccarani, Daniela Cilloni, Michela Rondoni, et al.
Cancer
|
January 3, 2014
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement
Simona Soverini, Caterina De Benedittis, Cristina Papayannidis, et al.
Page
of 17